March 4, 2011
Acuros Paper Selected for PMB Highlights of 2010

Paper on Acuros selected by Physics in Medicine and Biology as one of the top papers in 2010. The papers were "selected for their presentation of outstanding new research, receipt of the highest praise from our international referees and the highest number of downloads last year".
Click here to see the PMB Highlights of 2010.
Click here to access the paper.

November 1, 2010
Varian Medical Systems Receives 510(k) Clearance for Acuros^® XB Advanced Dose Calculation Algorithm for Planning Radiotherapy and Radiosurgery.

"New algorithm enables superior dose calculation at unmatched speed."
(Click Here) to see the full press release on the Varian Medical Systems website.

June 21, 2009
Varian Medical Systems Receives 510(k) Clearance for Fast and Accurate Acuros^® Radiotherapy Treatment Planning Capability.

(Click Here) to see the full press release on the Varian Medical Systems website.

September 25, 2008
Transpire, Inc. Co-Founders Receive 2008 Federal Laboratory Consortium Award for Excellence in Technology Transfer for the Commercialization of Attila.

The Federal Laboratory Consortium (FLC) awards are a prestigious honor in the technology transfer world, with dozens of federal laboratories submitting nominations each year. These awards have become a great source of pride for both the laboratories and their government agencies.The FLC annually presents its Award for Excellence in Technology Transfer to recognize those who have accomplished outstanding work in the process of transferring a technology developed by a federal laboratory to the commercial marketplace.

Winners are selected by a distinguished panel of technology transfer experts from industry, state and local government, academia, and the federal laboratory system. To visit the FLC awards website, (click here). To see the 2008 FLC Awards Program, (click here).

We would also like to express our sincere thanks to the Department of Energy SBIR program and Idaho National Laboratories, both of which provided funding for the extension of Attila’s capabilities towards reactor analysis, including the soon to be introduced activation source generation and depletion modules in Attila.

September 23, 2008
Attila Tutorial to be held at the ANS Winter Meeting

A hands on Attila Tutorial, sponsored by RPSD, will be held on Wednesday, November 13th, at 1-4 PM, at the ANS Winter Meeting in Reno, NV. The Attila tutorial is a hands-on session where attendees will learn how to set-up and run simple problems with the deterministic transport code Attila. It is designed for those who have never run Attila before. Software will be provided for the participants to perform the calculations during the tutorial. While it is recommended that the participants bring their own laptop, additional laptops will be brought to the session so that everyone will be able to participate hands-on. Our sincere thanks to Charlotta Sanders (UNLV) and the RPSD for sponsoring this session.

May 23, 2008
Transpire, Inc. Receives EN ISO 9001: 2000 Certification

Transpire, Inc. has been certified by the National Standards Authority of Ireland (NSAI) to be in accordance with the I.S. EN ISO 9001:2000 standard. The registration scope covers the development and delivery of software solutions, software related training and engineering services, in the field of radiation transport simulations.

March 31, 2008
Transpire, Inc. Featured in The Wall Street Journal

Transpire, Inc. was featured in The Wall Street Journal in an article titled “Skilled-Worker Visa Applicants Expected to Soar” (March 31, 2008, Page A2, by Miriam Jordan). The article discusses the pressing need for highly skilled workers in specialized technology fields, and profiled Transpire’s business as a case study.

March 24, 2008
Attila Tutorial to be Held at ICRS-11

A hands-on Attila tutorial will be held at ICRS-11, April 13-18, Callaway Gardens, Pine Mountain Georgia.

September 19, 2007
  TRANSPIRE AWARDED A PHASE II STTR GRANTTRANSPIRE AWARDED A PHASE II STTR GRANTTRANSPIRE AWARDED A PHASE II STTR GRANTTRANSPIRE AWARDED A PHASE II STTR GRANTTRANSPIRE AWARDED A PHASE II STTR GRANTTRANSPIRE AWARDED A PHASE II STTR GRANTTRANSPIRE AWARDED A PHASE II STTR GRANTTranspire, Inc. Awarded a Phase II STTR Grant From the National Cancer Institute 

Transpire received a Phase II Small Business Technology Transfer (STTR) grant from the National Cancer Institute to develop a commercially viable software reconstruction platform for pre-clinical optical imaging using fluorescent and bioluminescent targets. The award, which is approximately $750,000 over two years, combines Transpire’s capabilities for accurately and efficiently solving the radiative transport equations with Baylor College of Medicine’s strengths in frequency domain photon migration measurement approaches and small animal imaging in the Frensley Center for Imaging Research. Participating faculty from the Department of Radiology at Baylor College of Medicine include Amit Joshi Ph.D., Eva Sevick Ph.D., John Rasmussen Ph.D., Shi Ke M.D., Tianshu Pan Ph.D., and Juliet Wendt M.D.

Successful completion of the Phase II research will provide a capability which may substantially improve the state-of-the-art in drug discovery and contribute significantly to improved understanding of disease processes. The resulting product may also benefit the translation of optical imaging agents into human clinical trials, especially for applications such as lymph node mapping, tumor margin definition in melanoma, and assessing lymphatic function in pediatric tumors.

September 18, 2007
Attila Workshop to be held at the 2008 International Nuclear Codes Workshop (MCNEG 2008)

An Attila workshop will be held at the 2008 International Nuclear Codes Workshop. This workshop is part of MCNEG 2008, the 14th annual conference organized by the UK forum for users of Monte Carlo Neutron Electron and Gamma radiation transport codes. Although the conference has traditionally focused solely on the application of Monte Carlo codes, Attila has been added this year due to its growing popularity. The meeting will be held on March 3-6, 2008 in Risley, Cheshire UK. For more information, click here.

July 9, 2007
Transpire, Inc. Awarded a Phase II SBIR Grant From the National Cancer Institute

Transpire received a Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to develop and validate a deterministic solver for clinical radiotherapy dose calculations. This award, which is approximately $745,000 over two years, will help fund the continued development of Acuros for all forms of photon beam radiotherapies. Since Acuros directly solves the governing transport equations for neutral and charged particles, much of this work will also benefit the migration of Acuros to other modalities. As part of this project, physicians and physicists from the Radiation Physics and Radiation Oncology Departments at the M.D. Anderson Cancer Center will participate in the clinical validation of Acuros®. Participating faculty include Firas Mourtada Ph.D., Kent Gifford Ph.D., Oleg Vassiliev Ph.D., John Horton Ph.D., Adam Garden M.D., Mohammad Salehpour Ph.D., and Eric Strom M.D. By providing a combination of speed and accuracy superior to existing clinical dose calculation methods, Acuros® has the potential to improve the quality of care for the approximately 650,000 patients receiving photon beam radiotherapy each year in the U.S., and many more worldwide.

July 1, 2007
Attila Approved as a Validated Code for ITER Neurtronics Analyses

Attila has recently been added to the short list of validated codes for ITER neutronics analyses. ITER (International Thermonuclear Experimental Reactor) is a joint international research and development project that aims to demonstrate the scientific and technical feasibility of fusion power. The partners in the project include the European Union, Japan, China, India, South Korea, Russia and the USA. ITER will be constructed in Europe, at Cadarache in the South of France. The Attila software is being applied by ITER participants for a broad range of CAD based neutronics design simulations.

November 12, 2005
  Transpire, Inc. Awarded a Phase I Small Business Technology Transfer (STTR) Grant From the Institutes of Health 

In this research, Transpire's expertise in the development and application for solving the radiative transport equation (RTE) will be leveraged for use within a commercially viable small animal optical imaging system. Quantitative in-vivo molecular imaging in small animals could revolutionize and enhance drug discovery as well as contribute significantly to new understanding of disease processes.

For such applications, optical imaging has a number of inherent advantages compared with nuclear imaging techniques (PET/SPECT): (i) animals may be genetically engineered to express fluorescent proteins, enabling a signal which can be directly imaged to dynamically assess metabolism; (ii) the participation of stem cells, viruses, and bacterial infections can be dynamically followed in-vivo by incorporating fluorescent 'tags' of varying excitation and emission spectra; (iii) therapeutic agents, gene delivery vehicles, and molecularly targeting proteins or inhibitors that can be innocuously labeled with fluorescent dyes and dynamically followed in their distribution and action in-vivo; and (iv) in the case of fluorescence, a fluorophore is not extinguished upon emission of a fluorescent photon as a radio-isotope is annihilated following gamma or beta emission. While optical imaging in small animals has appeared in a number of commercial units, to date there are no validated animal tomographic imaging systems available. This is in part due to the lack of sufficiently accurate RTE based methods which can resolve visible light transport in small animals.

In the Phase I research, Transpire's advanced solution algorithms will be applied towards the modeling of time-dependent light propagation in tomographic images from measurements of fluorescence, frequency-domain photon migration, pioneered by Professor Eva Sevick-Muraca and her colleagues, formerly at Texas A&M University. As part of this research, Professor Sevick-Muraca (Head of the Division of Molecular Imaging at Baylor College of Medicine), Dr. Amit Joshi (Research Associate), and John Rasmussen (Research Assistant), will work with Transpire to validate this approach using weighted back projection and inverse optimization algorithms for the reconstruction of fluorophore image concentrations within a mouse phantom. Dr. Edward Larson (Professor of Nuclear Engineering, University of Michigan), a recognized leader in the development of theoretical and applied radiation transport methods, is a consultant on this research. If successful, this research will lead to the development of an automated process which can greatly advance the state-of-the-art in small animal imaging.

Octorber 1, 2005
  Transpire, Inc. Awarded a Phase II  Small Business Innovation Research (SBIR) Grant U.S. Department of Energy 

Transpire will develop a reactor analysis program which can improve the performance, safety, and reliability of current and next generation nuclear power systems. Next generation reactor designs, regardless of the specific technology, will need increased accuracy and efficiency to meet customer and market demands, reduce large reserved design margins and engineering costs, and meet cost/performance expectations. Current reactor analysis tools, which rely on empirical approximations calibrated for existing light water reactors, are ill-suited for the design and operation of new reactor concepts. There is a compelling need for the development of accurate, transport based reactor simulation tools.

In this research, Transpire will leverage existing Attila® capabilities to develop a generally applicable, first-principles based reactor life cycle analysis system. Framatome ANP, a worldwide leader in the nuclear power industry, will provide applications expertise and consultation throughout this research. Simmetrix, Inc. a provider of state-of-the-art CAD based mesh generation solutions, will also provide development expertise. Through an unprecedented combination of accuracy, efficiency, and ease-of-use, the resulting product will help realize the goal of developing a safe and economically viable long term energy solution.